REFERENCES
1. El-deiry WS, Goldberg RM, Lenz H, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin 2019;69:305-43.
2. Latha NR, Rajan A, Nadhan R, et al. Gene expression signatures: a tool for analysis of breast cancer prognosis and therapy. Crit Rev Oncol Hematol 2020;151:102964.
3. Garufi G, Carbognin L, Arcanà C, et al. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: which role for gene expression assays? Cancer Treat Rev 2022;110:102454.
4. Vallon-christersson J, Häkkinen J, Hegardt C, et al. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Sci Rep 2019;9:12184.
5. Doll S, Gnad F, Mann M. The case for proteomics and phospho-proteomics in personalized cancer medicine. Prot Clin Appl 2019;13:1800113.
6. Liu Y, Beyer A, Aebersold R. On the dependency of cellular protein levels on mRNA abundance. Cell 2016;165:535-50.
7. Cioce M, Sacconi A, Donzelli S, et al. Breast cancer metastasis: is it a matter of OMICS and proper ex-vivo models? Comput Struct Biotechnol J 2022;20:4003-8.
8. Dahlgren M, George AM, Brueffer C, et al. Preexisting somatic mutations of estrogen receptor alpha (
9. Macdonald SM, Paznekas WA, Jabs EW. Chromosomal localization of tumor protein, translationally-controlled 1 (TPT1) encoding the human histamine releasing factor (HRF) to13q12→q14. Cytogenet Cell Genet 1999;84:128-9.
10. Bommer U, Telerman A. Dysregulation of TCTP in biological processes and diseases. Cells 2020;9:1632.
11. Consortium. Uniprot: the universal protein knowledgebase in 2023. Nucleic Acids Res 2023;51:D523-31.
12. Susini L, Besse S, Duflaut D, et al. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ 2008;15:1211-20.
13. Thaw P, Baxter NJ, Hounslow AM, Price C, Waltho JP, Craven CJ. Structure of TCTP reveals unexpected relationship with guanine nucleotide-free chaperones. Nat Struct Biol 2001;8:701-4.
14. Dong X, Yang B, Li Y, Zhong C, Ding J. Molecular basis of the acceleration of the GDP-GTP exchange of human ras homolog enriched in brain by human translationally controlled tumor protein. J Biol Chem 2009;284:23754-64.
15. Bommer U, Kawakami T. Role of TCTP in cell biological and disease processes. Cells 2021;10:2290.
16. Yağcı M, Yegin ZA, Akyürek N, et al. TCTP/HRF pathway and angiogenesis: a feasible intercourse in chronic lymphocytic leukemia. Leuk Res 2013;37:665-70.
17. Børset M, Elsaadi S, Vandsemb EN, et al. Highly expressed genes in multiple myeloma cells - what can they tell us about the disease? Eur J Haematol 2022;109:31-40.
18. Amson R, Pece S, Lespagnol A, et al. Reciprocal repression between P53 and TCTP. Nat Med 2012;18:91-9.
19. Lucibello M, Adanti S, Antelmi E, et al. Phospho-TCTP as a therapeutic target of dihydroartemisinin for aggressive breast cancer cells. Oncotarget 2015;6:5275-91.
20. Chen C, Deng Y, Hua M, et al. Expression and clinical role of TCTP in epithelial ovarian cancer. J Mol Histol 2015;46:145-56.
21. Zhu X, Ren J, Xu D, et al. Upregulation of translationally controlled tumor protein is associated with cervical cancer progression. Front Mol Biosci 2021;8:686718.
22. Zhang F, Ma Q, Xu Z, et al. Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer. J Exp Clin Cancer Res 2017;36:68.
23. Zhang F, Liu B, Wang Z, et al. A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression. Mol Cancer Res 2013;11:1508-20.
24. Miao X, Chen YB, Xu SL, et al. TCTP overexpression is associated with the development and progression of glioma. Tumour Biol 2013;34:3357-61.
25. Gu X, Yao L, Ma G, et al. TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced β-catenin/TCF-4 transcription. Neuro Oncol 2014;16:217-27.
26. Slaby O, Sobkova K, Svoboda M, et al. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol Rep 2009;21:1235-41.
27. Xiao B, Chen D, Luo S, et al. Extracellular translationally controlled tumor protein promotes colorectal cancer invasion and metastasis through Cdc42/JNK/ MMP9 signaling. Oncotarget 2016;7:50057-73.
28. Baylot V, Katsogiannou M, Andrieu C, et al. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol Ther 2012;20:2244-56.
29. Rocca BJ, Ginori A, Barone A, et al. Translationally controlled tumor protein in prostatic adenocarcinoma: correlation with tumor grading and treatment-related changes. Biomed Res Int 2015;2015:985950.
30. Sun R, Lu X, Gong L, Jin F. TCTP promotes epithelial-mesenchymal transition in lung adenocarcinoma. Onco Targets Ther 2019;12:1641-53.
31. Liu LZ, Wang M, Xin Q, Wang B, Chen GG, Li MY. The permissive role of TCTP in PM2.5/NNK-induced epithelial-mesenchymal transition in lung cells. J Transl Med 2020;18:66.
32. Phanthaphol N, Techasen A, Loilome W, et al. Upregulation of TCTP is associated with cholangiocarcinoma progression and metastasis. Oncol Lett 2017;14:5973-9.
33. Kobayashi D, Hirayama M, Komohara Y, et al. Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors. J Biol Chem 2014;289:26314-26.
34. Ramani P, Nash R, Sowa-Avugrah E, Rogers C. High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas. J Neurooncol 2015;125:103-11.
35. Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010;140:62-73.
36. Santoro A, Vlachou T, Luzi L, et al. p53 Loss in breast cancer leads to myc activation, increased cell plasticity, and expression of a mitotic signature with prognostic value. Cell Rep 2019;26:624-38.e8.
37. Yucer N, Ahdoot R, Workman MJ, et al. Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis. Cell Rep 2021;37:110146.
38. Rae C, Amato F, Braconi C. Patient-derived organoids as a model for cancer drug discovery. Int J Mol Sci 2021;22:3483.
39. Yarm FR. Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol Cell Biol 2002;22:6209-21.
40. Cucchi U, Gianellini LM, De Ponti A, et al. Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. Anticancer Res 2010;30:4973-85. Available from: https://pubmed.ncbi.nlm.nih.gov/21187478/. [Last accessed on 12 Jul 2023]
41. Lemmens B, Hegarat N, Akopyan K, et al. DNA replication determines timing of mitosis by restricting CDK1 and PLK1 activation. Mol Cell 2018;71:117-28.e3.
42. Malard F, Assrir N, Alami M, Messaoudi S, Lescop E, Ha-Duong T. Conformational ensemble and biological role of the TCTP intrinsically disordered region: influence of calcium and phosphorylation. J Mol Biol 2018;430:1621-39.
43. Combes G, Alharbi I, Braga LG, Elowe S. Playing polo during mitosis: PLK1 takes the lead. Oncogene 2017;36:4819-27.
44. Rizki A, Mott JD, Bissell MJ. Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res 2007;67:11106-10.
45. King SI, Purdie CA, Bray SE, et al. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom. Breast Cancer Res 2012;14:R40.
46. Montaudon E, Nikitorowicz-Buniak J, Sourd L, et al. PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. Nat Commun 2020;11:4053.
47. Bhola NE, Jansen VM, Bafna S, et al. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res 2015;75:405-14.
48. Donizy P, Halon A, Surowiak P, Kaczorowski M, Kozyra C, Matkowski R. Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up. Oncol Lett 2016;12:1667-74.
49. D’Amico S, Krasnowska EK, Manni I, et al. DHA affects microtubule dynamics through reduction of phospho-TCTP levels and enhances the antiproliferative effect of T-DM1 in trastuzumab-resistant HER2-positive breast cancer cell lines. Cells 2020;9:1260.
50. Gioia D, Stieber P, Schmidt GP, Nagel D, Heinemann V, Baur-Melnyk A. Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase. Br J Cancer 2015;112:809-18.
51. Kawakami Y, Kasakura K, Kawakami T. Histamine-releasing factor, a new therapeutic target in allergic diseases. Cells 2019;8:1515.
52. Kim M, Choe Y, Lee H, et al. Blockade of translationally controlled tumor protein attenuated the aggressiveness of fibroblast-like synoviocytes and ameliorated collagen-induced arthritis. Exp Mol Med 2021;53:67-80.
53. Zhang L, Xiao H, Karlan S, et al. Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One 2010;5:e15573.
54. Kim JE, Koo KH, Kim YH, Sohn J, Park YG. Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model. Exp Mol Med 2008;40:709-20.
55. Freitas AJA, Causin RL, Varuzza MB, et al. Liquid biopsy as a tool for the diagnosis, treatment, and monitoring of breast cancer. Int J Mol Sci 2022;23:9952.
56. Amzallag N, Passer BJ, Allanic D, et al. TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway. J Biol Chem 2004;279:46104-12.
57. Chen M, Xu R, Ji H, et al. Transcriptome and long noncoding RNA sequencing of three extracellular vesicle subtypes released from the human colon cancer LIM1863 cell line. Sci Rep 2016;6:38397.
58. Ferrer E, Dunmore BJ, Hassan D, et al. A potential role for exosomal translationally controlled tumor protein export in vascular remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2018;59:467-78.
59. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 2016;37:208-20.
60. Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer 2022;21:184.
61. Hangai S, Kawamura T, Kimura Y, et al. Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells. Nat Immunol 2021;22:947-57.
62. Sangaletti S, Tripodo C, Santangelo A, et al. Mesenchymal transition of high-grade breast carcinomas depends on extracellular matrix control of myeloid suppressor cell activity. Cell Rep 2016;17:233-48.
63. Chen X, Feng L, Huang Y, Wu Y, Xie N. Mechanisms and strategies to overcome PD-1/PD-L1 blockade resistance in triple-negative breast cancer. Cancers 2022;15:104.
64. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017;168:707-23.
65. Lee HJ, Song KH, Oh SJ, et al. Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes. Nat Commun 2022;13:2127.
66. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 2019;20:69-84.
67. Yang J, Antin P, Berx G, et al. EMT International Association (TEMTIA). Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2020;21:341-52.
69. Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol 2019;29:212-26.
70. Lee MY. Embryonic programs in cancer and metastasis-insights from the mammary gland. Front Cell Dev Biol 2022;10:938625.
71. Chen SH, Wu PS, Chou CH, et al. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol Biol Cell 2007;18:2525-32.
72. Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 2007;445:785-8.
73. Kwon YV, Zhao B, Xu C, et al. The role of translationally controlled tumor protein in proliferation of
74. Zhang Q, Cheng Z, Shi L, Mao G. miR-145-5p inhibits the proliferation of glioma stem cells by targeting translationally controlled tumor protein. J Cancer 2022;13:1490-500.
75. Bae SY, Kim HJ, Lee KJ, Lee K. Translationally controlled tumor protein induces epithelial to mesenchymal transition and promotes cell migration, invasion and metastasis. Sci Rep 2015;5:8061.
76. Mishra DK, Srivastava P, Sharma A, et al. Translationally controlled tumor protein (TCTP) is required for TGF-β1 induced epithelial to mesenchymal transition and influences cytoskeletal reorganization. Biochim Biophys Acta Mol Cell Res 2018;1865:67-75.
77. Bazile F, Pascal A, Arnal I, Le Clainche C, Chesnel F, Kubiak JZ. Complex relationship between TCTP, microtubules and actin microfilaments regulates cell shape in normal and cancer cells. Carcinogenesis 2009;30:555-65.
78. Lucibello M, Gambacurta A, Zonfrillo M, et al. TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. Exp Cell Res 2011;317:2479-89.
79. Bommer UA, Vine KL, Puri P, et al. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Commun Signal 2017;15:9.
80. Jeong M, Jeong MH, Kim JE, et al. TCTP protein degradation by targeting mTORC1 and signaling through S6K, Akt, and Plk1 sensitizes lung cancer cells to DNA-damaging drugs. Sci Rep 2021;11:20812.
81. Jung J, Lee JS, Lee YS, Lee K. Radiosensitivity of cancer cells is regulated by translationally controlled tumor protein. Cancers 2019;11:386.
82. Sinha P, Kohl S, Fischer J, et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 2000;21:3048-57.
83. Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol 2022;12:819128.
84. Vora P, Venugopal C, Salim SK, et al. The rational development of CD133-targeting immunotherapies for glioblastoma. Cell Stem Cell 2020;26:832-44.e6.
85. Sambasivan S. Epithelial ovarian cancer: review article. Cancer Treat Res Commun 2022;33:100629.
86. Yang W, Kim D, Kim DK, Choi KU, Suh DS, Kim JH. Therapeutic strategies for targeting ovarian cancer stem cells. Int J Mol Sci 2021;22:5059.
88. Zhang P, Wu W, Chen Q, Chen M. Non-coding RNAs and their integrated networks. J Integr Bioinform 2019;16:20190027.
89. Li Y, Li F, Sun Z, Li J. A review of literature: role of long noncoding RNA TPT1-AS1 in human diseases. Clin Transl Oncol 2023;25:306-15.
90. Hu C, Fang K, Zhang X, Guo Z, Li L. Dyregulation of the lncRNA TPT1-AS1 positively regulates QKI expression and predicts a poor prognosis for patients with breast cancer. Pathol Res Pract 2020;216:153216.
91. Huang Y, Zheng Y, Shao X, Shi L, Li G, Huang P. Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis. Hum Cell 2021;34:1244-54.
92. Elango R, Vishnubalaji R, Shaath H, Alajez NM. Transcriptional alterations of protein coding and noncoding RNAs in triple negative breast cancer in response to DNA methyltransferases inhibition. Cancer Cell Int 2021;21:515.
93. Wu W, Gao H, Li X, et al. LncRNA TPT1-AS1 promotes tumorigenesis and metastasis in epithelial ovarian cancer by inducing TPT1 expression. Cancer Sci 2019;110:1587-98.
94. Efferth T. From ancient herb to modern drug: artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol 2017;46:65-83.
95. Yu R, Jin G, Fujimoto M. Dihydroartemisinin: a potential drug for the treatment of malignancies and inflammatory diseases. Front Oncol 2021;11:722331.
96. Ericsson T, Blank A, von Hagens C, Ashton M, Äbelö A. Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol 2014;70:1453-63.
97. von Hagens C, Walter-Sack I, Goeckenjan M, et al. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). Breast Cancer Res Treat 2017;164:359-69.
98. Deeken JF, Wang H, Hartley M, et al. A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol 2018;81:587-96.
99. Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist Updat 2005;8:85-97.
100. Bhisutthibhan J, Pan XQ, Hossler PA, et al. The plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J Biol Chem 1998;273:16192-8.
101. Fujita T, Felix K, Pinkaew D, Hutadilok-Towatana N, Liu Z, Fujise K. Human fortilin is a molecular target of dihydroartemisinin. FEBS Lett 2008;582:1055-60.
102. Denkert C, Lambertini C, Fasching PA, et al. Biomarker data from the phase III KATHERINE study of adjuvant T-DM1 versus trastuzumab for residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. Clin Cancer Res 2023;29:1569-81.
103. Tarantino P, Corti C, Schmid P, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer 2022;8:23.
104. Duarte D, Vale N. Antidepressant drug sertraline against human cancer cells. Biomolecules 2022;12:1513.
105. Tuynder M, Fiucci G, Prieur S, et al. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci U S A 2004;101:15364-9.
106. Boia-Ferreira M, Basílio AB, Hamasaki AE, et al. TCTP as a therapeutic target in melanoma treatment. Br J Cancer 2017;117:656-65.
107. Chinnapaka S, Bakthavachalam V, Munirathinam G. Repurposing antidepressant sertraline as a pharmacological drug to target prostate cancer stem cells: dual activation of apoptosis and autophagy signaling by deregulating redox balance. Am J Cancer Res 2020;10:2043-65. Available from: https://pubmed.ncbi.nlm.nih.gov/32775000/. [Last accessed on 12 Jul 2023]
108. Li Y, Sun H, Zhang C, et al. Identification of translationally controlled tumor protein in promotion of DNA homologous recombination repair in cancer cells by affinity proteomics. Oncogene 2017;36:6839-49.
109. Malard F, Jacquet E, Nhiri N, et al. Revisiting the molecular interactions between the tumor protein TCTP and the drugs sertraline/thioridazine. ChemMedChem 2022;17:e202100528.
110. Cerma K, Piacentini F, Moscetti L, et al. Targeting PI3K/AKT/mTOR pathway in breast cancer: from biology to clinical challenges. Biomedicines 2023;11:109.
111. Frappaolo A, Karimpour-Ghahnavieh A, Cesare G, et al. GOLPH3 protein controls organ growth by interacting with TOR signaling proteins in Drosophila. Cell Death Dis 2022;13:1003.
112. Le TP, Vuong LT, Kim AR, Hsu YC, Choi KW. 14-3-3 proteins regulate Tctp-Rheb interaction for organ growth in Drosophila. Nat Commun 2016;7:11501.
113. Bommer UA, Iadevaia V, Chen J, Knoch B, Engel M, Proud CG. Growth-factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the PI3-K/Akt/mTORC1 signalling pathway. Cell Signal 2015;27:1557-68.
114. Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol 2014;25:2357-62.
115. R Core Team (2022). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: https://www.R-project.org/. [Last accessed on 12 Jul 2023]
